Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Cholesterol and the risk of grade-specific prostate cancer incidence: evidence from two large prospective cohort studies with up to 37 years' follow up.

Shafique K, McLoone P, Qureshi K, Leung H, Hart C, Morrison DS.

BMC Cancer. 2012 Jan 19;12:25. doi: 10.1186/1471-2407-12-25.

2.

Tea consumption and the risk of overall and grade specific prostate cancer: a large prospective cohort study of Scottish men.

Shafique K, McLoone P, Qureshi K, Leung H, Hart C, Morrison DS.

Nutr Cancer. 2012 Aug;64(6):790-7. doi: 10.1080/01635581.2012.690063. Epub 2012 Jun 14.

PMID:
22697604
3.

Coffee consumption and prostate cancer risk: further evidence for inverse relationship.

Shafique K, McLoone P, Qureshi K, Leung H, Hart C, Morrison DS.

Nutr J. 2012 Jun 13;11:42. doi: 10.1186/1475-2891-11-42.

4.

Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).

Russo AL, Chen MH, Aizer AA, Hattangadi JA, D'Amico AV.

BJU Int. 2012 Oct;110(7):973-9. doi: 10.1111/j.1464-410X.2012.11470.x.

5.

Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis.

Gann PH, Ma J, Giovannucci E, Willett W, Sacks FM, Hennekens CH, Stampfer MJ.

Cancer Res. 1999 Mar 15;59(6):1225-30.

6.

5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer.

Preston MA, Wilson KM, Markt SC, Ge R, Morash C, Stampfer MJ, Loda M, Giovannucci E, Mucci LA, Olumi AF.

JAMA Intern Med. 2014 Aug;174(8):1301-7. doi: 10.1001/jamainternmed.2014.1600.

7.

Serum β-carotene in relation to risk of prostate cancer: the Kuopio Ischaemic Heart Disease Risk Factor study.

Karppi J, Kurl S, Laukkanen JA, Kauhanen J.

Nutr Cancer. 2012 Apr;64(3):361-7. doi: 10.1080/01635581.2012.658949. Epub 2012 Mar 16.

PMID:
22420939
8.

Blood lipid levels and prostate cancer risk; a cohort study.

Kok DE, van Roermund JG, Aben KK, den Heijer M, Swinkels DW, Kampman E, Kiemeney LA.

Prostate Cancer Prostatic Dis. 2011 Dec;14(4):340-5. doi: 10.1038/pcan.2011.30. Epub 2011 Jul 5.

PMID:
21727905
9.

Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer.

Hammarsten J, Högstedt B.

Eur J Cancer. 2005 Dec;41(18):2887-95. Epub 2005 Oct 20.

PMID:
16243513
10.

Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort.

Mondul AM, Clipp SL, Helzlsouer KJ, Platz EA.

Cancer Causes Control. 2010 Jan;21(1):61-8. doi: 10.1007/s10552-009-9434-8. Epub 2009 Oct 6.

11.

Dietary intakes of carbohydrates in relation to prostate cancer risk: a prospective study in the Malmö Diet and Cancer cohort.

Drake I, Sonestedt E, Gullberg B, Ahlgren G, Bjartell A, Wallström P, Wirfält E.

Am J Clin Nutr. 2012 Dec;96(6):1409-18. doi: 10.3945/ajcn.112.039438. Epub 2012 Nov 7.

12.

Agent Orange exposure, Vietnam War veterans, and the risk of prostate cancer.

Chamie K, DeVere White RW, Lee D, Ok JH, Ellison LM.

Cancer. 2008 Nov 1;113(9):2464-70. doi: 10.1002/cncr.23695.

13.

Association of vasectomy and prostate cancer among men in a Maryland cohort.

Rohrmann S, Paltoo DN, Platz EA, Hoffman SC, Comstock GW, Helzlsouer KJ.

Cancer Causes Control. 2005 Dec;16(10):1189-94.

PMID:
16215869
14.

Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials.

Nanda A, Chen MH, Renshaw AA, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1419-23. doi: 10.1016/j.ijrobp.2008.10.027. Epub 2009 Jan 7.

PMID:
19131185
15.

Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.

Brasky TM, Darke AK, Song X, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM, Parnes HL, Klein EA, Kristal AR.

J Natl Cancer Inst. 2013 Aug 7;105(15):1132-41. doi: 10.1093/jnci/djt174. Epub 2013 Jul 10.

16.

Factors associated with treatment received by men diagnosed with prostate cancer in Queensland, Australia.

Baade PD, Youlden DR, Gardiner RA, Ferguson M, Aitken JF, Yaxley J, Chambers SK.

BJU Int. 2012 Dec;110(11 Pt B):E712-9. doi: 10.1111/j.1464-410X.2012.011533.x. Epub 2012 Sep 27.

17.

Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years.

Lund Håheim L, Wisløff TF, Holme I, Nafstad P.

Am J Epidemiol. 2006 Oct 15;164(8):769-74. Epub 2006 Sep 4.

18.

Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort.

Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE.

Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2213-7. Epub 2007 Oct 30.

19.

Plasma total, LDL, and HDL cholesterol and risk of aggressive prostate cancer in the Cancer Prevention Study II Nutrition Cohort.

Jacobs EJ, Stevens VL, Newton CC, Gapstur SM.

Cancer Causes Control. 2012 Aug;23(8):1289-96. doi: 10.1007/s10552-012-0006-y. Epub 2012 Jun 13.

PMID:
22692409
20.

Statin drugs and risk of advanced prostate cancer.

Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, Giovannucci E.

J Natl Cancer Inst. 2006 Dec 20;98(24):1819-25.

Items per page

Supplemental Content

Write to the Help Desk